Abstract
Review of “Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial” by Davies et al. (2013), Lancet, 381, 805–816. For another perspective on the ATLAS trial, please see the article on randomization and adjusting for covariates by Dustin Dickerson starting on page 61.
